Please assess the completion status of the following clinical trial:

Trial Title: A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 11.0

Eligibility Criteria:
Inclusion Criteria:~* Unilateral limb ischemia - Society of Vascular Surgery Categories I and IIa~* Onset of symptoms less than or equal to 14 days~* Thrombosed infrainguinal bypass graft or native artery~* Diagnosis by arteriography of occlusive thrombus in graft or artery~* Ability to embed the infusion catheter into the thrombus~* Women of childbearing potential must use contraception and have a negative pregnancy test~Exclusion Criteria:~* Any medical or social condition that may interfere with study participation~* Women who are pregnant or lactating~* Hemorrhagic stroke history~* Thrombotic or embolic stroke or cerebrovascular events (including transient ischemic attack) within one year~* Intracranial or spinal neurosurgery, or severe intracranial trauma in the last 3 months~* Major surgery, organ biopsy, or major trauma within the past 10 days~* Lumbar puncture or non-compressible arterial puncture in the past 10 days~* Intraocular surgery within the past 10 days~* Active gastrointestinal or organ bleeding~* Uncontrolled arterial hypertension (systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg)~* Known intracranial neoplasm, aneurysm, or arteriovenous malformation~* Current bleeding diathesis~* Platelet count \<75 x 10e9/L~* Active graft infection~* Occlusion occurred within one month of synthetic graft placement~* Occlusion occurred within 6 months of autologous graft placement~* A sequential composite graft with dual outflows to correct multiple occlusions~* Medically unable to tolerate an open vascular procedure~* Known prothrombotic state~* Hemoglobin \<10.0 g/dL~* Impaired renal function or renal disease that constitutes a contraindication to contrast angiography, including creatinine \>2.0 mg/dL~* Treatment with a full dose plasminogen activator (PA) within the last 48 hours~* Treatment with a glycoprotein IIb/IIIa class of platelet inhibitor within the past 5 days~* Treatment with oral anticoagulants, and with an international normalized ratio of \>1.7

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Plasmin Open-label Treatment Group A (Type: EXPERIMENTAL): Open-label 150 mg Plasmin administered without initial proximal pulse; 5-hour infusion using 10 mL/hour infusion rate.
- Plasmin Open-label Treatment Group B (Type: EXPERIMENTAL): Open-label 150 mg Plasmin administered with initial proximal pulse; 5-hour infusion using 15 mL/hour infusion rate
- Plasmin Open-label Treatment Group C (Type: EXPERIMENTAL): Open-label 150 mg Plasmin administered with proximal pulse; 5 hour infusion using 30 mL/hour infusion rate.
- Plasmin Open-label Treatment Group D (Type: EXPERIMENTAL): Open-label 150 mg Plasmin administered with proximal pulse; 2-hour infusion using 35 mL/hour infusion rate
- Plasminogen Activator Blinded Group E (Type: ACTIVE_COMPARATOR): PA administered for five hours at a dose and volume according to the Investigator's clinical judgement/standard practice
- PA Placebo Blinded Treatment Arm F (Type: PLACEBO_COMPARATOR): PA placebo (normal saline for injection) administered for five hours at a dose and volume according to the Investigator's clinical judgement/standard practice for PA administration
- Plasmin Open-label Treatment Group G (Type: EXPERIMENTAL): Open-label 150 mg Plasmin administered without pulsing; 5-hour infusion using 60 mL/hour infusion rate
- Plasmin Open-label Treatment Group H (Type: EXPERIMENTAL): Open-label 150 mg Plasmin administered without pulsing; 2-hour infusion using 75 mL/hour infusion rate
- Plasmin Open-label Treatment Group I (Type: EXPERIMENTAL): Open-label 150 mg Plasmin administered without pulsing; 5-hour infusion using 30 mL/hour infusion rate with balloon occlusion catheter
- Plasmin Open-label Treatment Group J (Type: EXPERIMENTAL): Open-label 150 mg Plasmin administered without pulsing; 2-hour infusion using 35 mL/hour infusion rate with balloon occlusion catheter
- Plasmin Open-label Treatment Group M (Type: EXPERIMENTAL): Open-label 250 mg Plasmin administered without pulsing; 5-hour infusion using 30 mL/hour infusion rate with balloon occlusion catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete